Synthetic hammerhead ribozymes as therapeutic tools to control disease genes

Current Gene Therapy

Volumn 5, Issue 1, 2005, Pages 11-24

  Citti, Lorenzo ^a   Rainaldi, G ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Gene drugs; Gene knockdown; Gene therapy; Hammerhead ribozymes; Synthetic oligonucleotides

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANGIOZYME; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; APTAMER; CATION; CIS ACTING ELEMENT; CISPLATIN; DRUG CARRIER; HAMMERHEAD RIBOZYME; HEPBZYME; HEPTAZYME; LIPOPLEX; METHYLPHOSPHONIC ACID; NITROSOUREA DERIVATIVE; OLIGOMER; PHOSPHOROTHIOIC ACID DERIVATIVE; POLYMER; RIBOZYME; RIBOZYME OZ1; RNA DERIVATIVE; SMALL INTERFERING RNA; TRANS ACTING FACTOR; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CATALYSIS; CLINICAL TRIAL; COVALENT BOND; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME THERAPY; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; GENE THERAPY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PRACTICE GUIDELINE; PROTEIN MOTIF; REVIEW; RNA CLEAVAGE; RNA SEQUENCE; RNA SYNTHESIS; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIROID; VIRUS INFECTION;

EID: 13844272635     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/1566523052997541     Document Type: Review

References (155)

1. Abounader, R., Lal, B., Luddy, C., Koe G., Davidson B., Rosen, E.M., Laterra, J. (2002) In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 16: 108-110.
2. Abounader, R., Ranganathan, S., Lal, B., Fielding, K., Book, A., Dietz, H., Burger, P., Laterra, J., (1999) Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting for scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. 91: 1548-1556.
3. Afroze, T., Husain, M. (2001) Cell cycle dependent regulation of intracellular calcium concentration in vascular smooth muscle cells: a potential target for drug therapy. Curr. Drug Targets Cardiovasc. Haematol. Disord. 1: 23-40.
4. Agrawal, S., Jiang, Z., Zhao, Q., Shaw., Cai, Q., Roskey, A., Channavajiala, L., Saxinger, C., Zhang, R. (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 94: 2620-2625.
5. Agrawal, S., Zhao, Q. (1998) Antisense Therapeutics. Curr. Opin. Chem. Biol. 2: 519-528.
6. Aigner, A., Fischer, D., Merdan, T., Brus, C., Kissel, F., Czubayko, F. (2002) Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther. 9: 1700-1707.
7. Akkina, R., Banerjea, A., Bai, J., Anderson, J., li, M.J., Rossi, J. (2003) siRNAs, ribozymes and RNA decoys in modelling stem cell-based gene therapy for HIV/AIDS. Anticancer Res. 23: 1997-1005.
8. Amarzguioui, M., Brede, G., Babaie, E., Grotli, M., Sproat, B., Prydz, H. (2000) Secondary structure prediction and in vitro accessibility of mRNA as tool in the selection of target sites for ribozymes. Nucl. Acids Res. 28: 4113-4124.
9. Bai, J., Banda, N., Lee, N.S., Rossi, J., Akkina, R. (2002) RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol. Ther. 6: 770-782.
10. Bertrand, E.L., Rossi, J.J. (1994) Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J. 13: 2904-2912.
11. Bi, F., Fan, D., Hui, H., Wang, C., Zhang, X. (2001) Reversion of the malignant phenotype of gastric cancer cells SGC7901 by c-erbB-2-specific hammerhead ribozyme. Cancer Gene Ther. 8: 835-842.
12. Biegelman, L., Karpeisky, A., Matulic-Adamic, J., Gonzalez, C., Usman, N. (1995) New structural motives for hammerhead ribozymes. Catalytic activity of abasic nucleotide substituted ribozymes. Nucleosides Nucleotides 14: 907-910 .
13. Biegelman, L., Karpeisky, A., Usman, N. (1995) Synthesis of 6-aza and 6-methylpyrimidine ribonucleotide and their incorporation into hammerhead ribozymes. Nucleosides Nucleotides 14: 895-899 .
14. Biegelman, L., McSwiggen, J., Draper, K., Gonzalez, C., Jensen, K., Karpeisky, A., Moak, A., Matulic-Adamic, J., DiRenzo, A., Haeberli, P., Sweedler, D., Tracz, D., Grimm, S., Wincott, F., Thackray, V., Usman, N. (1995) Chemical modification of hammerhead ribozymes: activity and nuclease resistance. J. Biol. Chem. 270: 25702-25708 .
15. Biessen, E.A.L., Vietsch, H., Rump, E.T., Fluiter, K., Kuiper, J., Bijsterbosch, M.K., VanBerkel, T.J.C. (1999) Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem. J. 340: 783-792.
16. Birik, K.R., Heaton, P.A., Eckstein, F. (1996) The structure function and application of the hammerhead ribozyme. Eur. J. Biochem. 245: 1-16.
17. Bratty, J., Chartrand, P., Ferbeyere, G., Cedergren, R. (1993) The hammerhead RNA domain, a model ribozyme. Biochim. Biophys. Acta 1216: 345-359.
18. Cantin, E.M., Podsakoff, G., Willey, D.E., Openshaw, H. (1992) Antiviral effects of herpes simplex virus specific anti-sense nucleic acids. Adv. Exp. Med. Biol. 312: 139-149.
19. Catalytic, R.N.A., Eckstein, F. and Lilley, D.M.J. Editors, Nucleic Acids and Molecular Biology, Vol. 10 (1996), Springer-Verlag , Berlin Heidelberg New york.
20. Cech, T.R. (1990) Self-splicing of group I introns. Annu. Rev. Biochem. 59: 543-568.
21. Cheng, J., Luo, J., Zhang, X., Hu, J., Hui, H., Wang, C., Stern, A. (2000) Inhibition of cell proliferation in HCC-9204 hepatoma cells by a c-myc specific ribozyme. Cancer Gene Ther. 7: 407-412.
22. Choi, K.S., Lee, T.H., Jung, M.H. (2003) Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther. 10: 87-95.
23. Citti, L., Boldrini, L., Nevischi, S., Mariani, L., Rainaldi, G. (1997) Quantitation of in vitro activity of synthetic trans-acting ribozymes using HPLC. BioTechniques 23: 898-903.
24. Citti, L., Eckstein, F., Capecchi, B., Mariani, L., Nevischi, S., Poggi, A., Rainaldi, G. (1999) Transient transfection of a synthetic hammerhead ribozyme targeted against humam MGMT gene to cells in culture potentiates the genotoxicity of the alkylation damage induced by mitozolomide. Antisene Nucl. Acid Drug Dev. 9: 125-133.
25. Cotton, M., Birnstiel, M.L. (1989) Ribozyme-mediated destruction of RNA in vivo. EMBO J. 8: 3861-3866.
26. Cowan, K.N., Jones, P.L., Rabinovitch, M. (2000) Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J. Clin. Invest. 105: 21-34.
27. Czubayko, F., Dowining, S.G., Hsieh, S.S., Goldstein, D.J., Lu, P.Y., Trapnell, B.C., Wellstein, A. (1997) Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Ther. 4: 943-949.
28. Dahm, S.C., Uhlenbeck, O.C. (1991) Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry 30 9464-9469.
29. DeLong, R.K., Nolting, A., Fisher, M., Chen, Q., Wickstrom, E., Kligshteyn, M., Demirdji, S., Caruthers, M., Juliano, R.L. (1997) Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phospohorothioate, phosphorodithioate, and methylphosphonate oligonucleoties in nude mice. Antisense Nucleic Acid Drug Dev. 7 71-77.
30. Denman, R.B. (1993) Using RNAFOLD to predict the activity of small catalytic RNAs. Biotechniques 15: 1090-1095.
31. Dorai, T., Goluboff, E.T., Olsson, C.A., Buttyan, R. (1997) Development of a hammerhead ribozyme against BCL-2. II Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res. 17: 3307-3312.
32. Dorai, T., Perlman, H., Walsh, K., Shabsigh, A., Goluboff, E.T., Olsson, C.A., Buttyan, R. (1999) A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int. J. Cancer 82 846-852.
33. Eckstein, F., Bramlage, B. (1999) The hammerhead ribozyme. Biopolymers. 52: 147-154
34. Eckstein, F. and Lilley, D.M.J. eds. (1996) Catalytic RNA. in Nucleic Acids and Molecular Biology. Vol. 10. Springer Verlag Berlin, Heidelberg, New York.
35. Ellington, A.D., Szostak, J.W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
36. Ellis, J., Rogers, J. (1993) Design and specificity of hammerhead ribozymes against calretinin mRNA. Nucl. Acids Res. 21: 5171-5178.
37. Fedor, M.J., Uhlenbeck, O.C. (1990) Substrate sequence effects on "hammerhead" RNA catalytic efficiency. Proc. Natl. Acad. Sci. USA 87: 1668-1672.
38. Fedor, M.J., Uhlenbeck, O.C. (1992) Kinetics of intermolecular cleavage by hammerhead ribozymes. Biochemistry 31 12042-12054.
39. Feng, Y., Kong, Y.Y., Wang, Y., Qi, G.R. (2001) Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes. J. Gastroenterol. Hepatol. 16: 1125-1130.
40. Folini, M., De Marco, C., Orlandi, L., Daidone, M.G., Zaffaroni, N. (2000) Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. Eur. J. Cancer 36: 2137-2145.
41. Folini, M., Pennati, M., Zaffaroni, N. (2002) Targeting human telomerase by antisense oligonucleotides and ribozymes. Curr. Med. Chem. 2: 605-612.
42. Frimerman, A., Welch, P.J., Jin, X., Eigler, N., Yei, S., Forrester, J., Honda, H., Makkar, R., Barber, J., Litvack, F. (1999) Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 99: 697-703.
43. Fuchs, S., Kornowski, R., Leon, M.B., Epstein, S.E. (2001) Anti-angiogenesis: A new potential strategy to inhibit restenosis Int. J. Cardiovasc. Intervent. 4: 3,6.
44. Gibson, S.A., Pellenz, C., Hutchison, R.E., Davey, F.R., Shillitoe, E.J. (2000) Induction of apoptosis in oral cancer cells by anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin. Cancer Res. 6: 213-222.
45. Grassi, G., Grassi, M., Platz, J., Bauriedel, G., Kandolf, R., Kuhn, A. (2001) Selection and characterization of active hammerhead ribozymes targeted against cyclin E and E2F1 full-length mRNA. Antisense Nucleic Acid Drug Dev. 11: 271-287.
46. Gu, J.L., Pei, H., Thomas, L., Nadler, J.L., Rossi, J.J., Lanting, L., Natarajan, R. (2001) Ribozyme-mediated inhibition of rat leukocyte-type 12-lipoxygenase prevents intimal hyperplasia in balloon-injuried rat carotid arteries. Circulation 103: 1446-1452.
47. Haseloff, J., Gerlach, W.L. (1988) Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334 585-591.
48. Hatanaka, H., Abe, Y., Naruke, M., Asai, S., Miyachi, H., Kawakami, T., Nagata, J., Kamochi, J., Kijima, H., Yamazaki, H., Scanlon, K.J., Ueyama, Y., Nakamura, M. (2001) Modulation of anti-multidrug resistance-associated protein (MRP) ribozyme. Anticancer Res. 21 879-885.
49. Heidenreich, O., Benseler, F., Fahrenholz, A., Eckstein, F. (1994) High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioates. J. Biol. Chem. 269: 2131-2138.
50. Heidenreich, O., Eckstein, F. (1992) Hammerhead ribozyme-mediated cleavage of the long terminal repeat of human immunodeficiency virus type I. J. Biol. Chem. 267: 1904-1909.
51. Heidenreich, O., Kang, S-H., Brown, D.A., Xu, X., Swiderski, P., Rossi, J.J., Eckstein, F., Nerenberg, M. (1995) Ribozyme-mediated RNA degradation in nuclei suspension. Nucl. Acids Res. 23: 2223-2228.
52. Henry, S.P., Zuckerman, J.E., Rojko, J., Hall, W.C., Harman, R.J., Kitchen, D., Crooke, S.T. (1997) Toxicological properties of several novel oligonucleotide analogs in mice. Anti Cancer Drug Dev. 12: 1-14.
53. Hertel, K.J., Herschlag, D., Uhlenbeck, O.C. (1994) A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry 33: 3374-3385.
54. Hertel, K.J., Pardi, A., Uhlenbeck, O.C., Koizumi, M., Ohtsuka, E., Uesugi, S., Cedergren, R., Eckstein, F., Gerlach, W.L., Hodgson, R., Symons, R.H. (1992) Numbering system for the hammerhead ribozyme. Nuc. Acids Res. 20: 3252.
55. Herynk, M.H., Stoeltzing, O., Reinmuth, N., Parikh, N.U., Abounader, R., Laterra, J., Radinsky, R., Ellis, L.M., Gallik, G.E. (2003) Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res. 63: 2990-2996.
56. Ho, S.P., Bao, Y., Lesher, T., Malhotra, R., Ma, L.Y., Fluharty, S.J., Sakai, R.R. (1998) Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat. Biotechnol. 16: 59-63.
57. Hu, W.Y., Fukuda, N., Kishioka, H., Nakayama, M., Satoh, C., Kanmatsuse, K. (2001) Hammerhead ribozyme targeting-human platelet-derived growth factor A-chain mRNA inhibited the proliferation of human vascular smooth muscle cells. Atherosclerosis 158: 321-329..
58. Hu, W.Y., Fukuda, N., Kotani, M., Kanmatsuse, K. (2002) Adenovirus-mediated transfer of ribozyme targeting platelet-derived growth factor A-chain mRNA unhibits growth of vascular smooth muscle cells from spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 39: 858-865.
59. Hudson, A.J., Normand, N., Ackroyd, J., Akhtar, S. (1999) Cellular delivery of hammerhead ribozymes conjugated to a transferrin antibody. Int. J. Pharm. 182: 49-58.
60. Huges, M.D., Hussain, M., Nawaz, Q., Sayyed, P., Akhtar, S. (2001) The cellular delivery of antisense oligonucleoties and ribozymes. Drug Discovery Today 6: 303-315.
61. Ideo, G., Bellobuono, A. (2002) New therapies for the treatment of chronic hepatitis C. Curr. Pharm. Des. 8: 959-966.
62. Irie, A., Anderegg, B., Kashani-Sabet, M., Ohkawa, T., Suzuki, T., Halks-Miller, M., Curiel, D.T., Scanlon, K.J. (1999) Therapeutic efficacy of an adenovirus-mediated anti H-ras ribozyme in experimental bladder cancer. Antisense Nucleic Acid Drug Dev. 9 341-349.
63. Jaeger, J.A., Turner, D.H., Zucker, M. (1989) Improved predictions of secondary structures for RNA. Proc. Natl. Acad. Sci. USA 86: 7706-7710.
64. Jackson, J.K., Liang, L.S., Hunter, W.L., Reynolds, M., Sandberg, J.A., Springate, C., Burt, H.M. (2002) The encapsulation of ribozymes in biodegradable polymeric matrices. Int. J. Pharm. 243: 43-55.
65. Jarvis, T.C., Alby, L.J., Beauty, A.A., Wincott, F.E., Beigelman, L., McSwiggen, J.A., Usman, N., Stinchcomb, D.T. (1996) Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA. RNA 2: 419-428.
66. Jarvis, T.C., Wincott, F.E., Alby, L.J., McSwiggen, J.A., Biegelman, L., Gustofson, J., DiRenzo, A., Levy, K., Arthur, M., Matulic-Adamich, J., Karpeisky, A., Gonzalez, C., Woolf, T.M., Usman, N., Stinchcomb, D.T. (1996) Optimizing the cell efficacy of synthetic ribozymes. Site selection and chemical moiofications of ribozymes targeting the proto-oncogene c-myb. J. Biol. Chem. 271: 29107-29112.
67. Jiang, W.G., Grimshaw, D., Lane, J., Martin, T.A., Abounader, R., Laterra, J., Mansel, R.E., Abounder, R. (2001) A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-met and reduces migration and invasiveness of breast cancer cells. Clin. Cancer Res. 7: 2555-2562.
68. Juliano, R.L., Alahari, S., Yoo, H., Kole, R., Cho, M. (1999) Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. 16: 494-502.
69. Ke, L.D., Fueyo, J., Chen, X., Steck, P.A., Shi, Y.X., Im, S.A., Yung, W.K. (1998) A novel approach to glyoma gene therapy: down-regulation of the vascular endothelial growth factor in glyoma cells using ribozymes. Int. J. Oncol. 12: 1391-1396.
70. Khan, A., Sommer, W., Fuxe, K., Akhtar, S. (2000) Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain. J. Drug Targeting 8: 319-334.
71. Kiessling, R., Weil, W.Z., Herrmann, F., Lindencrona, J.A., Choundhry, A., Kono, K., Seliger, B. (2002) Cellular immunity to the Her-2/neu protooncogene. Adv. Cancer Res. 85: 101-144.
72. Kijima, H., Scanlon, K.J. (2000) Ribozyme as an approach for growth suppression of human pancreatic cancer. Mol. Biotechnol. 14: 59-72.
73. Kobayashi, H., Takemura, Y., Miyachi, H. (2001) Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics. Hum. Cell 14: 172-184.
74. Kotani, M., Fukuda, N., Ando, H., Hu, W.Y., Kunimoto, S., Saito, S., Kanmatsuse, K. (2003) Chimeric DNA-RNA hammerhead ribozyme targeting PDGF A-chain mRNA specifically inhibits neointima formation in rat carotid artery after ballon injury. Cardiovasc. Res. 57: 265-276.
75. Kuimelis, R.G., McLaughlin, L.W. Probing the cleavage activity of the hammerhead ribozyme using analog complexes. In "Catalytic RNA", Eckstein F. and Lilley D.M.J. Editors, in Nucleic Acids and Molecular Biology, Vol. 10 (1996), Springer-Verlag , Berlin Heidelberg New York. pp.197-215.
76. Kurreck, J. (2003) Antisense technologies. Improvements through novel chemical modifications Eur. J. Biochem. 270: 1628-1644.
77. Kuwabara, T., Tanabe, T., Warashina, M., Xiong, K.X., Tani, K., Taira, K., Asano, S. (2001) Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice. Biomacromolecules 2: 1220-1228.
78. Lazarev, V.N., Shmarov, M.M., Zakhartchouk, A.N., Yurov, G.K., Misurina, O.U., Akopian T.A., Grinenko N.F., Grodnitskaya N.G., Kaverin N.V., Naroditsky B.S. (1999) Inhibition of influenza A virus reproduction by a ribozyme targeted against PB1 mRNA. Antiviral Res. 42: 47-57.
79. Li, S., Deshmukh, H.M., Huang, L. (1998) Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm. Res. 15: 1540-1545.
80. Lieber, A., Strauss, M. (1995) Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol. Cell Biol. 15: 540-551.
81. Ludwig, A., Saretzki, G., Holm, P.S., Tiemann, F., Lorenz, F., Emrich, T., Harley, C.B., von Zglinicki, T. (2001) Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerases. Cancer Res. 61: 3053-3061.
82. Lui, V.W., He, Y., Huang, L. (2001) Specific down-regulation of Her-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. Mol. Ther. 3: 169-177.
83. Luzi, E., Papucci, L., Schiavone, N., Donnini, M., Lapucci, A., Tempestini, A., Witort, E., Nicolin, A., Capaccioli, S. (2003) Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme. Cancer Gene Ther. 10 201-208.
84. Macejak, D.G., Lin, H., Webb, S., Chase, J., Jensen, K., Jarvis, T.C., Leiden, J.M., Couture, L. (1999) Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo. J. Virol. 73: 7745-7751.
85. + cells to the alkylating antineoplastic drug. Cancer Gene Ther. 7: 905-909.
86. Mathews, D.H., Burkard, M.E., Freier, S.M., Wyatt, J.R., Turner, D.H. (1999) Predicting oligonucleotide affinity to nucleic acid targets. RNA 5: 1458-1469.
87. Mathews, D.H., Sabina, J., Zucker, M., Turner, D.H. (1999) Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol. 288: 911-940.
88. Mendoza-Maldonado, R., Zentilin, L., Fanin, R., Giacca, M. (2002) Purging of chronic myelogenous leukemia cells by retrovirally expressed anti bcr-abl ribozymes with specific cellular compartmentalization. Cancer Gene Ther. 9: 71-86.
89. Mercatanti, A., Rainaldi, G., Mariani, L., Marangoni, R., Citti, L. (2002) A method for prediction of accessibile sites on an mRNA sequenze for target selection of hammerhead ribozymes. J. Computat. Biol. 9: 641-653.
90. Michel, F., Umesono, K., Ozeki, H. (1989) Comparative and functional anatomy of group II catalytic introns a review. Gene 82: 5-30.
91. Morishita, R., Yamada, S., Yamamoto, K., Tomita, N., Kida, I., Sakurabayashi, I., Kikuchi, A., Kaneda, Y., Lawn, R., Higaki, J., Ogihara, T. (1998) Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein (a) selectively inhibit apolipoprotein (a) but not plasminogen gene expression. Circulation 98: 1898-1904.
92. Morris, M.C., Vidal, P., Chaloin, L., Heitz, F., Divita, G. (1997) A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25: 2730-2736.
93. Morrissey, D.V., Lee, P.A., Johnson, D.A., Overly, S.L., McSwiggen, J.A., Beigelman, L., Mokler, V.R., Maloney, L., Vargeese, C., Bowman, K., O'Brien, J.T., Shaffer, C.S., Conrad, A., Schmid, P., Morrey, J.D., Macejak, D.G., Pavco, P.A., Blatt, L.M. (2002) Characterization of nuclease-resistant ribozymes directed against hepatitis B RNA. J. Viral. Hepat. 9: 411-418.
94. Musio, A., Montagna, C., Zambroni, D., Indino, E., Barbieri, O., Citti, L., Villa, A., Ried, T., Vezzoni, P. (2003) Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts. Cancer Res. 63: 2855-2863.
95. Nagata, J., Kijima, H., Hatanaka, H., Asai, S., Miyachi, H., Abe, Y., Yamazaki, H., Nakamura, M., Watanabe, N., Mine, T., Kondo, T., Scanlon, K.J., Ueyama, Y. (2002) Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. Int. J. Oncol. 21: 1021-1026.
96. Nason-Burchenal, K., Allopenna, J., Begue, A., Stehelin, D., Dmitrovsky, E., Martin, P. (1998) Targeting PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood 92 1758-1767.
97. Nason-Burkenal, K., Takle, G., Pace, U., Flynn, S., Allopenna, J., Martin, P., George, S.T., Goldberg, A.R., Dmitrovsky, E. (1998) Targeting the PML/RARalpha translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene 17: 1759-1768.
98. Osada, H., Tokunaga, T., Abe, Y., Asai, S., Miyachi, H., Hatanaka, H., Tsugu, A., Kijima, H., Yamazaki, H., Shima, K., Ueyama, Y., Osamura, Y., Nakamura, M. (2003) Reversal of dru resistance mediated by hammerhead ribozyme against multidrug resistance -associated protein 1 in a human glioma cell line. Int. J. Oncol. 22: 823-827.
99. Pace, N.R., Brown, J.W. (1995) Evolutionary perspective on the structure and function of ribonuclease P, a ribozyme. J. Bacteriol. 177: 1919-1928.
100. Pan, W-H., Devlin, H.F., Kelley, C., Isom, H.C., Clawson, G.A. (2001) A selection system for identifying accessible sites in target RNAs. RNA 7: 610-621.
101. Parry, T.J., Cushman, C., Gallegos, A.M., Agrawal, A.B., Richardson, M., Andrews, L.E., Maloney, L., Mokler, V.R., Wincott, F.E., Pavco, P.A. (1999) Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res. 27: 2569-2577.
102. Parthasarathy, R., Cote, G.J., Gagel, R.F. (1999) Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res. 59: 3911-3914.
103. Pavco, P.A., Bouhana, K.S., Gallegos, A.M., Agrawal, A., Blanchard, K.S., Grimm, S.L., Jensen, K.L., Andrews, L.E., Wincott, F.E., Pitot, P.A., Tressler, R.J., Cushman, C., Reynolds, M.A., Parry, T.J. (2000) Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clinical Cancer Res. 6: 2094-2103.
104. Pennati, M., Binda, M., Colella, G., Folini, M., Citti, L., Villa, R., Daidone, M.G., Zaffaroni, N. (2003) Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J. Invest. Dermatol. 120: 648-654.
105. Pennati, M., Binda, M., Colella, G., Zoppé, M., Folini, M., Vignati, S., Valentini, A., Citti, L., DeCesare, M., Pratesi, G., Giacca, M., Daidone, M.G., Zaffaroni, N. (2004) Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells Oncogene 23: 386-394.
106. Pennati, M., Colella, G., Folini, M., Citti, L., Daidone, M.G., Zaffaroni, N. (2002) Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J. Clin. Invest. 109: 285-286.
107. Piganeau, N., Thuillier, V., Famulok, M. (2001) In vitro selection of allosteric ribozymes : theory and experimental validation. J. Mol. Biol. 312: 1177-1190.
108. Poliseno, L., Bianchi, L., Citti, L., Liberatori, S., Mariani, L., Salvetti, A., Evangelista, M., Bini, L., Pallini, V., Rainaldi, G. (2004) Bcl2-low expressing MCF7 cells undergo necrosis rather than apoptosis upon staurosporine treatment. Biochem. J. 379: 823-832 .
109. Pouton, C.W., Seymour, L.W. (2001) Key issues in non-viral gene delivery. Adv. Drug Delivery Rev. 46: 187-203.
110. Putney, S.D., Brown, J., Cucco, C., Lee, R., Skorski, T., Leonetti, C., Geiser, T., Calabretta, B., Zupi, G., Zon, G. (1999) Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. Antisense Nucleic Acid Drug Dev. 9: 451-458.
111. Rojanasakul, Y., Weissman, D.N., Shi, X., Castranova, V., Ma, J.K., Liang, W. (1997) Antisense inhibition of silica-induced tumor necrosis factor in alveolar macrophages. J. Biol. Chem. 272: 3910-3914.
112. Rossi, J.J. (1999) The application of ribozymes to HIV infection. Curr. Opin. Mol. Ther. 1: 316-322 .
113. Ruffner, D.E., Stormo, G.D., Uhlenbeck, O.C. (1990) Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 29: 10695-10702.
114. Ruffner, D.E., Uhlenbeck, O.C. (1990) Thiophosphate interference experiments locate phosphate important for the hammerhead RNA self-cleavage reaction. Nucl. Acis Res. 18: 6025-6029 .
115. Sakamoto, N., Wu, C.H., Wu, G.Y. (1996) Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes J. Clin. Invest. 98: 2720-2728.
116. Sandberg, J.A., Bouhana, K.S., Gallegos, A.M., Agrawal, A.B., Grimm, S.L., Wincott, F.E., Reynolds, M.A., Pavco, P.A., Parry, T.J. (1999) Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. Antisense Nucleic Acid Drug Dev. 9: 271-277.
117. Sandberg, J.A., Parker, V.P., Blanchard, K.S., Sweedler, D., Powell, J.A., Kachensky, A., Bellon, L., Usman, N., Rossing, T., Borden, E., Blatt, L.M. (2000) Pharmacokinetics and tolerability of an antiangiogenetic ribozyme (ANGIOZYME) in healthy volunteers J. Clin. Pharmacol. 40: 1462-1469.
118. Sandberg, J.A., Sproul, C.D., Blanchard, K.S., Bellon, L., Sweedler, D., Powell, J.A., Caputo, F.A., Kornbrust, D.J., Parker, V.P., Parry, T.J., Blatt, L.M. (2000) Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey. Antisense Nucleic Acid Drug Dev. 10: 153-162.
119. Santa Lucia, J. Jr. (1998) A unified view of polymer, dumbell and oligonucleotide DNA nearest-neighbor thermodynamics. Proc. Natl. Acad. Sci. USA 95: 1460-1465.
120. Santoro, M., Melillo, R.M., Carlomagno, F., Fusco, A., Vecchio, G. (2002) Molecular mechanisms of RET activation in human cancer. Ann. N. Y. Acad. Sci. 963: 116-121.
121. Scherr, M., Maurer, A.B., Klein, S., Ganser, A., Engels, J.W., Grez, M. (1998) Effective reversal of a transformed phenotype by retrovirus-mediated transfer of a ribozyme directed against mutant N-ras. Gene Ther. 5: 1227-1234.
122. Scherr, M., Rossi, J.J. (1998) Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cells extracts. Nucl. Acids Res. 26: 5079-5085.
123. Scherr, M., Rossi, J.J., Sczakiel, G., Patzel, V. (2000) RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts. Nucl. Acids Res. 28: 2455-2461.
124. Schwab, G., Chavany, C., Duroux, I., Goubin, G., Lebeau, J., Helene, C., Saisonbehmoaras, T. (1994) Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated H-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA 91: 10460-10464.
125. Schwarze, S.R., Dowdy, S.F. (2000) In vivo protein transduction: intracellular delivery of biologically active proteins, compounds an DNA. Trends Pharmacol. Sci. 21: 45-48.
126. Scott, W.G., Finch, J.T., Klug, A. (1995) The crystal structure of an all-RNA hammerhead ribozyme: a proposed mechanism for RNA catalytic cleavage. Cell 81: 991-1002.
127. Shimayama, T., Nishikawa, F., Nishikawa, S., Taira, K. (1993) Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages. Nucl. Acids Res. 21: 2605-2611 .
128. Shimayama, T., Nishikawa, S., Taira, K. (1995) Generality of the NUX rule Kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes. Biochemistry 34: 3649-3654.
129. Sioud, M. (1997) Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates. Nucl. Acids Res. 25: 333-338.
130. Slim, G., Gait, M.J. (1991) Configurationally defined phosphorothioate-containing oligoribonucleotides in the study of the mechanism of cleavage of hammerhead ribozymes. Nucl. Acids Res. 19: 1183-1188.
131. Sproat, B.S. (1996) Synthetic catalytic oligonucleotides based on the hammerhead ribozyme. In "Catalytic RNA", F. Eckstein and D.M.J. Lilley Ed.s, Nucleic Acids an Molecular Biology, Vol. 10, Springer-Verlag, Berlin, Heidelberg, New York. pp 265-281 .
132. Stein, C.A., Subasinge, C., Shinozuka, K., Choen, J.S. (1988) Physicochemical properties of phosphorothioate oligonucleotides. Nucleic Acids Res. 16: 3209-3221 .
133. Su, J.Z., Fukuda, N., Hu, W.Y., Kanmatsuse, K. (2000) Ribozyme to human TGF-beta1 mRNA inhibits the proliferation of human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 278 401-407.
134. Sullenger, B.A., Gilboa, E. (2002) Emerging clinical applications of RNA. Nature 418: 252-258.
135. Suwanai, H., Matsushita, H., Kobayashi, H., Ikeda, Y., Kizaki, M. (2002) A novel therapeutic technology of specific RNA inhibition for acute promyelocytic leukemia: improved design of maxizymes against PML/RARalpha mRNA. Int. J. Oncol. 20: 127-130.
136. Symons, R.H. (1992) Small catalytic RNAs. Ann. Rev. Biochem. 61: 641-671.
137. Teng, J., Fukuda, N., Hu, W.Y., Nakayama, M., Kishioka, H., Kanmatsuse, K. (2000) DNA-RNA chimeric hammerhead ribozyme to transforming growth factor-beta(1) mRNA inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats. Cardiovasc. Res. 48: 138-147.
138. Tokunaga, T., Tsuchida, T., Kijima, H., Okamoto, K., Oshika, Y., Sawa, N., Ohnishi, Y., Yamazaki, H., Miura, S., Ueyama, Y., Nakamura, M. (2000) Ribozyme mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. Br. J. Cancer 83: 833-839.
139. Trang, P., Lee, K., Kiliani, A.F., Kim, J., Liu, F. (2001) Effective inhibition of herpes simplex virus 1 gene expression and growth by engineered RNase P ribozyme. Nucleic Acids Res. 29: 5071-5078.
140. Trang, P., Lee, M., Nepomuceno, E., Kim, J., Zhu, H., Liu, F. (2000) Effective inhibition of human cytomegalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia Coli. Proc. Natl. Acad. Sci. USA 97: 5812-5817.
141. Tsukioka, K., Suzuki, J., Fujimori, M., Wada, Y., Yamaura, K., Ito, K., Morishita, R., Kaneda, Y., Isobe, M., Amano, J. (2002) Expression of matrix metalloproteinases in cardiac allograft vasculopathy an its attenuation by anti MMP-2 ribozyme gene transfection. Cardiovasc. Res. 56: 472-478.
142. Tuerk, C., MacDougal-Waugh, S. (1993) In vitro evolution of functional nucleic acids: high-affinity RNA ligands of HIV-1 proteins..
143. Uhlenbeck, O.C. (1987) A small catalytic oligoribonucleotide. Nature 328: 596-600.
144. Usman, N., Blatt, L.M. (2000) Nuclease resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. 106: 1197-1202.
145. Wang, C.H., Tsai, L.J., Tsao, Y.P., Hsieh, J.T., Chien, W.W., Liao, C.L., Wang, H.W., Liu, H.S., Chen, S.L. (2002) Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways. Biochem Biophys. Res. Commun. 15: 805-814.
146. Wang, H., Chen, X.P., Qiu, F.Z. (2003) Overcoming multi-drug resistance by anti-MDR1 ribozyme. World J. Gastroenterol. 9: 1444-1449.
147. Weng, D.E., Usman, N. (2001) Angiozyme: a novel angiogenesis inhibitor. Curr. Oncol. Rep. 3: 141-146.
148. Wu, H., McLeod, A.R., Lima, W.F., Crooke, S.T. (1998) Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. J. Biol. Chem. 273: 2532-2542.
149. Yamada, O., Yu, M., Yee, J.K., Kraus, G., Looney, D., Wong-Staal, F. (1994) Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther. 1: 34-45.
150. Yamamoto, K., Morishita, R., Tomita, N., Shimozato, T., Nakagami, H., Kikuchi, A., Aoki, M., Higaki, J., Kaneda, Y., Ogihara, T. (2000) Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 102: 1302-1314.
151. Yoo, H., Juliano, R.I. (2000) Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers Nucleic Acids Res. 28: 4225-4231.
152. 6-methylguanine DNA methyltransferase mRNA. J. Pharmacol. Exp. Ther. 298: 141-147.
153. Zhang, Y.A., Nemunaitis, J., Scanlon, K.J., Tong, A.W. (2000) Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Ther. 7: 2041-2050.
154. Zoumadakis, M., Tablet, M. (1995) Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes. Nucl. Acids Res. 23: 1192-1196.
155. Zucker, M. (1989) On finding all suboptimal foldings of an RNA molecule. Science 244: 48-52.